Apellis Pharmaceuticals Inc [NASDAQ: APLS] stock went on an upward path that rose over 2.06% on Thursday, amounting to a one-week price increase of more than 0.54%.
Over the last 12 months, APLS stock dropped by -56.28%. The one-year Apellis Pharmaceuticals Inc stock forecast points to a potential upside of 43.73. The average equity rating for APLS stock is currently 1.74, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $3.05 billion, with 124.50 million shares outstanding and 104.48 million shares in the current float. Compared to the average trading volume of 1.75M shares, APLS stock reached a trading volume of 2788271 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Apellis Pharmaceuticals Inc [APLS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for APLS shares is $43.15 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on APLS stock is a recommendation set at 1.74. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Goldman have made an estimate for Apellis Pharmaceuticals Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on December 17, 2024. While these analysts kept the previous recommendation, Morgan Stanley raised their target price to Equal-Weight. The new note on the price target was released on November 21, 2024, representing the official price target for Apellis Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $25, while RBC Capital Mkts analysts kept a Sector Perform rating on APLS stock.
The Average True Range (ATR) for Apellis Pharmaceuticals Inc is set at 1.08, with the Price to Sales ratio for APLS stock in the period of the last 12 months amounting to 3.90. The Price to Book ratio for the last quarter was 13.23, with the Price to Cash per share for the same quarter was set at 3.29.
APLS Stock Performance Analysis:
Apellis Pharmaceuticals Inc [APLS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.54. With this latest performance, APLS shares dropped by -7.79% in over the last four-week period, additionally sinking by -21.04% over the last 6 months – not to mention a drop of -56.28% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for APLS stock in for the last two-week period is set at 40.21, with the RSI for the last a single of trading hit 42.59, and the three-weeks RSI is set at 39.92 for Apellis Pharmaceuticals Inc [APLS]. The present Moving Average for the last 50 days of trading for this stock 27.18, while it was recorded at 24.05 for the last single week of trading, and 32.37 for the last 200 days.
Insight into Apellis Pharmaceuticals Inc Fundamentals:
Apellis Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.81 and a Current Ratio set at 4.25.
Apellis Pharmaceuticals Inc [APLS] Institutonal Ownership Details
There are presently around $103.15%, or 119.74%% of APLS stock, in the hands of institutional investors. The top three institutional holders of APLS stocks are: WELLINGTON MANAGEMENT GROUP LLP with ownership of 16.39 million shares, which is approximately 13.2269%. ECOR1 CAPITAL, LLC, holding 11.61 million shares of the stock with an approximate value of $$445.26 million in APLS stocks shares; and ECOR1 CAPITAL, LLC, currently with $$426.22 million in APLS stock with ownership which is approximately 8.9675%.
